非格司亭防治卵巢癌化疗后骨髓抑制继发感染的临床分析  

Filgrastim in Prevention and Treatment of Postchemotherapy Leukopenia for Ovarian Cancer: A Clinical Analysis

作　　者：张巧[1] 邓文慧[1] 王新英[2] 

机构地区：[1]卫生部北京医院,北京100730 [2]莱州市人民医院,山东莱州261400

出　　处：《中华医院感染学杂志》2005年第1期79-81,共3页Chinese Journal of Nosocomiology

摘　　要：目的研究不同方法应用非格司亭(格拉诺赛特)对卵巢癌化疗后白细胞和中性粒细胞减少的防治作用。方法将96例的卵巢上皮性癌术后需化疗的患者随机分为A、B、C、D组,A组(共111个化疗周期)和B组(共61个周期)为治疗性应用,分别为白细胞计数<2.0×109/L和1.0×109/L时给予非格司亭,50μg/d和150μg/d,C组(共126个疗程)自化疗结束后48h起给予非格司亭50μg/d,均皮下注射;D组(共89疗程)不用非格司亭。结果C组白细胞最低值的持续时间明显短于A、B和D组(P<0.01),平均最低值分别为3.01×109/L和0.97×109/L,A、B组较D组短,但差异无显著性。结论非格司亭可维持白细胞和中性粒细胞的水平,减低感染的发生,预防性用药优于治疗性用药。OBJECTIVE To investigate the efficacy of different regimen of filgrastim (Granocyte, rhG-CSF) on leukopenia and neutropenia induced by chemotherapy in ovarian cancer patients. METHODS Ninety six ~postoperative patients with ovarian cancer treated with chemotherapy were randomized into three groups. In groups A (111 courses) and B (61 courses) 50 μg/d and 150 μg/d of rhG-CSF were given with WBC less than ~1.0×109/L and less than 2.0×109/L, respectively, while in group C (126 courses) 48 hours after chemotherapy filgrastim was given 50 g/d hypodermically, for patients in group D (89 courses) rhG-CSF was not given. ~RESULTS The time to nadir was significantly shorter in group C compared with groups A and B and revealed ~10 days for the WBC count and 11 days for the neutrophil count (P<0.01), with mean nadir values of 3.01×109/L and 0.97×109/L, respectively, and so the count of WBC and neutrophil have been kept during the course. CONCLUSIONS The results demonstrate the filgrastim increases WBC and neutrophil count and reduce the ~occurrence of ~inflammation. Preventive regimen is better than therapeutic one.

关 键 词：上皮性卵巢癌 化疗 骨髓抑制 非格司亭 感染 

分 类 号：R969.4[医药卫生—药理学]